Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122366 · ClinicalTrials.gov registry record
TLR4 Polymorphisms and Risk of Skin Cancer
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 392
- Enrollment target
NCT03122366 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 392 participants.
The verdict
NCT03122366 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 392 participants
- Enrollment target
Study Summary
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.
Interventions
- DIAGNOSTIC_TEST Detection of single nucleotide polymorphisms (SNP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2009-02-02 |
| Est. Completion | 2011-09-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122366
The ClinicalTrials.gov registry entry for NCT03122366 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Detection of single nucleotide polymorphisms (SNP) is the first listed.
NCT03122366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122366 about?
NCT03122366 is a clinical study titled "TLR4 Polymorphisms and Risk of Skin Cancer". Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, d...
What is the current status of trial NCT03122366?
This trial is currently completed. The enrollment target is 392 participants. The study started on 2009-02-02. Estimated completion is 2011-09-27.
What interventions are being tested in trial NCT03122366?
The interventions under investigation include: Detection of single nucleotide polymorphisms (SNP) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03122366?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.